{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Minor Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Progression of Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","groups":[{"description":"The proposed study is designed as a Phase II, multi-center trial of lenalidomide intensification in patients with asymptomatic POD while on low dose lenalidomide maintenance after HDM/ASCT or on continuous/maintenance therapy after initial treatment.","id":"OG000","title":"Lenalidomide"}],"paramType":"NUMBER","populationDescription":"A total of 10 patients were evaluable for the primary endpoint of response.","reportingStatus":"POSTED","timeFrame":"6 months","title":"Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"participants"}